학술논문
Efficacy of COVID-19 vaccines: Several modes of expression should be presented in scientific publications.
Document Type
Academic Journal
Author
Montastruc JL; Service de Pharmacologie Médicale et Clinique, CIC INSERM 1436, Centre Hospitalier Universitaire-Faculté de Médecine, Toulouse, France.; Biron P; Faculté de Médecine, Université de Montréal, Montréal, Canada.; Sommet A; Service de Pharmacologie Médicale et Clinique, CIC INSERM 1436, Centre Hospitalier Universitaire-Faculté de Médecine, Toulouse, France.
Source
Publisher: Blackwell Science Country of Publication: England NLM ID: 8710411 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1472-8206 (Electronic) Linking ISSN: 07673981 NLM ISO Abbreviation: Fundam Clin Pharmacol Subsets: MEDLINE
Subject
Language
English
Abstract
Several vaccines are being developed as part of the COVID-19 pandemic. The results of clinical trials for these vaccines were published with efficacy values of more than 90%, using mainly relative risk (RR). In this paper, we decided to reanalyse the data using the different validated methods of risk expression. Using main publications, absolute risks (AR), AR reduction (ARR), number needed to treat (NNT) were calculated for five COVID-19 vaccines (tozinameran Comirnaty®, Moderna, Vaxzevria®, Janssen, and Sputnik V vaccines). AR, ARR, NNT, and RR values varied according to COVID-19 vaccines. The order of the different vaccines was not the same according to the chosen efficacy parameters. This is a further example of the need to express results of clinical trials, using not only RR, but also AR, ARR, and NNT in order to clearly present the clinical interest of drugs.
(© 2021 Société Française de Pharmacologie et de Thérapeutique.)
(© 2021 Société Française de Pharmacologie et de Thérapeutique.)